Human Health in Extreme ConditionsNCT07065253
CHOICE KERGUELEN 1: Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands: Inclusion of Volunteers Before Departure to the Kerguelen Islands
An observational study of Human Health in Extreme Conditions, run by University Hospital, Angers at 1 site in France.
Trial summary
Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Human Health in Extreme Conditions
- What is being tested?
- blood ponction, urines collection and hair collection
- How many people
- 0 participants
- Where
- 1 siteFrance
- Study dates
- 25 Sep 2025to 25 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: French civic service volunteer
Who may be able to join
- healthy people aged > 18 years
- Participant affiliated with or benefiting from a social security system
- Participant has signed informed consent
- Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
Who cannot join
- age < 18 years
- Pregnant, breastfeeding, or postpartum woman
- immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
- Person refusing to participate in the study
- Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
- Person undergoing involuntary psychiatric treatment
- Person subject to a legal protection measure
Trial locations and contacts
1 site in 1 country.
About this study
Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.
These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.
To help fill this gap, the CHOICE Kerguelen 1 study will recrut a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen 1 study is conducted in collaboration with the French Polar Institute (IPEV).The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers before they leave for the island, to have baseline medical state and baseline biological samples. These samples will integrate in to healthy volunteer biobank of CHU Angers, a type of biological archive that provided control samples for CHOICE Kerguelen 2 - a clinical study relating to follow-up of volunteers during civic service on the Kerguelen Islands
- Conditions
- Human Health in Extreme Conditions
- Being tested
- blood ponction, urines collection, hair collection, saliva collection, stools collection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood ponctionOther
blood ponction
urines collectionOther
urines collection
hair collectionOther
hair collection
saliva collectionOther
saliva collection
stools collectionOther
stools collection
| Study group | Role | What they receive |
|---|---|---|
| HD (healthy donors) | Not described Receives: Other: blood ponction; Other: urines collection; Other: hair collection; Other: saliva collection; Other: stools collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood samples
Blood samples
Measured: At inclusion (before overwintering)
Saliva samples
Saliva samples
Measured: At inclusion (before overwintering)
Urine samples.
morning urine samples.
Measured: At inclusion (before overwintering)
Hair samples
Hair samples
Measured: At inclusion (before overwintering)
Stool samples
Stool samples
Measured: At inclusion (before overwintering)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2025
- Study start25 Sep 2025
- Primary completion25 Sep 2025
- Study completion25 Sep 2025
Why it stopped: No ethic approval
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Health in Extreme ConditionsStudies of the same condition, open and under way.
- More trials run by University Hospital, AngersThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Angers
- Sponsor type
- Other government
- Collaborators
- Institut Polaire Français Paul-Emile Victor (IPEV)
- Responsible party
- Sponsor
- Investigators
- Charline MIOT, Principal investigator, University Hospital, Angers
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07065253
- Sponsor's protocol ID
- 49RC25_0245
- Status last verified
- Jul 2026
- First submitted
- 3 Jul 2025
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CHOICE KERGUELEN 1: Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands: Inclusion of Volunteers Before Departure to the Kerguelen Islands
- ClinicalTrials.gov ID
- NCT07065253
- Acronym / sponsor ID
- 49RC25_0245
- Conditions
- Human Health in Extreme Conditions
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: No ethic approval
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital, AngersOther government
- Collaborators
- Institut Polaire Français Paul-Emile Victor (IPEV)
- Study start
- 25 Sep 2025 (actual)
- Primary completion
- 25 Sep 2025 (actual)
- Study completion
- 25 Sep 2025 (actual)
- First posted
- 15 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.
These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.
To help fill this gap, the CHOICE Kerguelen 1 study will recrut a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen 1 study is conducted in collaboration with the French Polar Institute (IPEV).The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers before they leave for the island, to have baseline medical state and baseline biological samples. These samples will integrate in to healthy volunteer biobank of CHU Angers, a type of biological archive that provided control samples for CHOICE Kerguelen 2 - a clinical study relating to follow-up of volunteers during civic service on the Kerguelen Islands
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HD (healthy donors) | – | Other: blood ponction, Other: urines collection, Other: hair collection, Other: saliva collection, Other: stools collection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- French civic service volunteer
Key inclusion criteria (4 listed)
- healthy people aged > 18 years
- Participant affiliated with or benefiting from a social security system
- Participant has signed informed consent
- Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
Key exclusion criteria (7 listed)
- age < 18 years
- Pregnant, breastfeeding, or postpartum woman
- immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
- Person refusing to participate in the study
- Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood ponctionblood ponction | Other | HD (healthy donors) |
| urines collectionurines collection | Other | HD (healthy donors) |
| hair collectionhair collection | Other | HD (healthy donors) |
| saliva collectionsaliva collection | Other | HD (healthy donors) |
| stools collectionstools collection | Other | HD (healthy donors) |
Primary outcome
Blood samples
Time frame: At inclusion (before overwintering)
Blood samples
Saliva samples
Time frame: At inclusion (before overwintering)
Saliva samples
Urine samples.
Time frame: At inclusion (before overwintering)
morning urine samples.
Hair samples
Time frame: At inclusion (before overwintering)
Hair samples
Stool samples
Time frame: At inclusion (before overwintering)
Stool samples
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Individual participant dataSharing planned: Yes. Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
Related trials for Human Health in Extreme Conditions
RecruitingObservational study
CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands
Human Health in Extreme Conditions
Active, not recruiting
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
Type 2 Diabetes Mellitus, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charline MIOT principal investigator
University Hospital, Angers
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Health in Extreme Conditions, run by University Hospital, Angers at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood samples (time frame: At inclusion (before overwintering)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.